Inovio combines optimized DNA with safe & effective delivery to generate significant T cells with killing activity.

- **Diverse strains/variants of a target virus/cancer**
- **Assess gene sequence of selected antigen from chosen strains/variants of the virus/cancer**
- **Synthetically create optimal consensus gene sequence for the selected antigen**
- **Insert synthetic consensus gene sequence for selected antigen into DNA plasmid**
- **Synthetic Consensus DNA**
- **Manufacture DNA vaccine**
- **Deliver vaccine into muscle or skin tissue using electroporation**
- **Protective universal antibodies and killer T-cells produced by immune system against diverse strains of a virus**
If untreated, moderate/severe cervical dysplasia (CIN2/3) may progress to invasive cancer.
LEEP is perceived to be highly effective, but there is concern of poor longer-term reproductive outcomes.

- Loop Electrosurgical Excision Procedure (LEEP) is the surgical procedure for treating abnormal, pre-cancerous cells on the cervix (cervical dysplasia).

- Although most women do not have any serious side effects after LEEP, risks include:
  - Heavy vaginal bleeding
  - Premature birth and having a low birth weight baby
  - Infertility/difficulty becoming pregnant
  - Menstrual problems

- Additionally, avoiding surgery is a powerful motivator even among women not considering childbirth.

http://www.hopkinsmedicine.org
LEEP is the surgical standard-of-care for the treatment of cervical dysplasia

- Loop Electrosurgical Excision Procedure (LEEP) uses a high-voltage electrical arc at 100°C to vaporize a plane through the cervix
- Followed by fulguration using a cauter
HPV is responsible for nearly 300,000 annual cases of high-grade cervical dysplasia (CIN2/3) in the US.

Incidence rates in the U.S.

- **HIGH GRADE DYSPLASIA (CIN2/3)**
  - 300,000 to 400,000 new cases

- **LOW GRADE DYSPLASIA (CIN1)**
  - 1,400,000 new cases

- **CERVICAL CANCERS**
  - 11,818 new cases

- **OROPHARYNGEAL CANCER**
  - 11,726 new cases

- **ANOGENITAL CANCERS**
  - 9,530 new cases

70% of high risk cervical pre-cancers & cancers caused by HPV types 16 & 18.

Source: President’s Cancer Panel Annual Report 2012-2013; CDC
VGX-3100: HPV16,18 E6/E7 Immunotherapy

*Deletions or mutations important for p53 binding and degradation
ΔMutations in Rb binding site
Phase II: Study Design

- Placebo-controlled, randomized, double blind
  - 148+ subjects: Females 18-55 years old
  - Histologically confirmed HPV16 or 18-associated CIN 2/3 or 3
  - 3:1 VGX-3100/electroporation vs. placebo/electroporation
  - Two plasmids: Type 16 and Type 18, each encoded for E6/E7 antigens; 3 mg/ml per plasmid; treatment at months 0, 1, 3

- **Primary endpoint** (Month 9)
  - Regression of CIN 2/3 to CIN 1 or no disease

- **Secondary endpoints**
  - Regression plus clearance of HPV 16 or 18 genotype detected during screening (Week 36)
  - Immunogenicity
  - Safety
Phase II: Study Timeline

Legend: S—Screening  E—Enrollment  Wk—Week  DC—Discharge

-10 weeks to -1 day (begins at initial biopsy)

Day 0  Wk 4  Wk 12  Wk 36

18 month Protocol
- 3 month (0, 4, 12 week) regimen
- +6 months to primary endpoint
- + 9 months long term follow-up
Subjects monitored for clinical progression of disease by

- Mandatory Pap smear and HPV PCR on cervical samples (Weeks 14, 62 and 88)
- Mandatory colposcopy with biopsy if clinically indicated (Week 24)

Colposcopy and/or biopsy can be performed at any time based upon suspicion of disease progression

Surgical excision of cervical lesions at Week 36

All biopsy and excised tissue sent to Pathology Adjudication Panel

Overall subjects are followed for safety for one year after surgical excision (Week 88)
CIN2/3 resolved to CIN1 or normal in a higher percentage of VGX-3100-treated patients vs. placebo-treated patients

Overall Histopathologic Regression Incidence
Per-Protocol* Population (N=143)

*Per-protocol population (PPP) includes subjects given 3 doses / EP who were biopsied or had surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36

PPP also includes subjects with suspected disease progression who underwent early intervention prior to this time frame or discontinued the study; these subjects are treated as non-regressors

Difference between VGX-3100 and placebo is statistically significant (p=0.017, strata-adjusted)

- VGX-3100: 49.5% (53/107)
- Placebo: 30.6% (11/36)
CIN2/3 resolved to CIN1 or normal with virological clearance of HPV 16 and/or 18 in a higher % of VGX-3100- vs. placebo-treated patients

Overall Histopathologic Regression* and Virological (HPV Type 16 or 18) Clearance Incidence Per-Protocol** Population (N=142)

*Defined as overall biopsy diagnosis or overall definitive therapy diagnosis as either CIN 1 or No Significant Pathological Change

**Per-protocol population (PPP) includes subjects given 3 doses / EP who were biopsied or had surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36

PPP also includes subjects with suspected disease progression who underwent early intervention prior to this time frame or discontinued the study; these subjects are treated as non-regressors

Difference between VGX-3100 and placebo is statistically significant (p=0.001, strata adjusted)

- **40.2%** (43/107) for VGX-3100
- **14.3%** (5/35) for Placebo
SUMMARY: VGX-3100 has the potential to address a high unmet medical need in the treatment of HPV-driven cervical dysplasia

- HPV 16 and 18 are responsible for nearly 300,000 cases of high-grade cervical dysplasia in the US annually

- There is a high unmet need for a non-surgical option that preserves a woman’s reproductive health

- VGX-3100 is generally well-tolerated with only administration site redness occurring significantly more frequently in the VGX-3100 group vs. placebo group

- Immunization with VGX-3100 results in regression of CIN2/3 to CIN1 or normal and virological clearance of HPV 16 and/or 18
  - 49.5% regression to CIN1 or less, 40.2% regression to CIN1 or less in the context of complete elimination of HPV 16/18 infection
VGX-3100: Next Steps

**ANALYSIS of PHASE II DATA IN PROGRESS**
- Additional immunological and histological data in progress
- Manuscript in preparation

**PHASE III in PLANNING UNDERWAY**
- Clinical and Regulatory
- Commercial EP Device Development
- Quantitative Market Research
- Supply Chain Strategy
- Pricing & Reimbursement

**EXPANSION of HPV PROGRAM to RELATED INDICATIONS**
- Cervical Cancer
  - Head & Neck
- Anogenital Cancers
  - VIN, PIN
Acknowledgements

Mark Bagarazzi
Jian Yan
Matthew Morrow
Anna Slager
Albert Sylvester
Niranjan Sardesai
J. Joseph Kim
Kate Broderick
Mary Giffear
Steve Kemmerer
Amir Khan
Jessica Lee
Laurent Humeau
Malissa Diehl
Mike Dallas
Rob Juba
Chris Knott
Jay McCoy
Sandi Oyola
Ami Shah Brown
Xuefei Shen
Maria Yang
Divya Shah
Kathleen Marcozzi-Pierce

Dorothy Peterson
Shane Johnson
Young Park

David Weiner
Jean Boyer